BRIEF—Mologen and Oncologie agree licensing deal for immunotherapy candidate

Berlin’s Mologen has agreed a deal with Boston, USA-based Oncologie related to the former’s lead immunotherapy candidate lefitolimod.

Oncologie will pay 3 million euros ($3.7 million) for the rights to develop, manufacture and commercialize the product in China. The deal also sets out a planned global co-development program.

Mologen chief executive Mariola Soehngen commended Oncologie’s “approach of an innovative biomarker-driven development strategy for novel cancer immunotherapies.”

“We have found a partner with a highly dedicated and experienced international team who will not only drive lefitolimod development in China to achieve market approval but will also strongly support our global development efforts,” she added.